About Intas
Intas is a company based in Ahmedabad (India) founded in 1977. Intas has raised $199.57 million across 4 funding rounds from investors including ChrysCapital and Tata Capital Healthcare Fund. The company has 19,974 employees as of February 28, 2025. Intas has completed 2 acquisitions, including Bioxel Pharma and Udenyca. Intas offers products and services including Pharmaceutical Formulations and Biologics.
- Headquarter Ahmedabad, India
- Employees 19974 as on 28 Feb, 2025
- Stage Soonicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Intas Pharmaceuticals Ltd
- Jurisdiction Ahmedabad, Gujarat, India
-
Annual Revenue
$2.41 B (USD)8.75as on Mar 31, 2023
-
Net Profit
$291.3 M (USD)-9.57as on Mar 31, 2023
-
EBITDA
$447.07 M (USD)-6.65as on Mar 31, 2023
-
Total Equity Funding
$199.57 M (USD)
in 4 rounds
-
Latest Funding Round
$132 M (USD), Private Equity Round
Jun 02, 2020
-
Investors
ChrysCapital
& 1 more
-
Employee Count
19974
as on Feb 28, 2025
-
Investments & Acquisitions
Bioxel Pharma
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Intas
Intas offers a comprehensive portfolio of products and services, including Pharmaceutical Formulations and Biologics.
Formulations such as tablets, injectables, and capsules are developed and manufactured for global distribution
Biologics and biosimilars, including plasma-derived products, are produced and marketed for therapeutic purposes
People of Intas
Unlock access to complete
Funding Insights of Intas
Intas has successfully raised a total of $199.57M across 4 strategic funding rounds. The most recent funding activity was a Private Equity Round of $132 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Intas
Intas has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include ChrysCapital and Tata Capital Healthcare Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment firm focusing on private equity in sectors like financial services and healthcare.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Intas
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intas
Intas has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bioxel Pharma and Udenyca.
Investment portfolio details for Intas
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Manufactures taxane active pharmaceutical ingredients for the healthcare industry.
|
Locked | Locked | 1995 | Locked | |
|
Developer of a prescription medicine to reduce infection risk in cancer patients
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Intas
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Intas
Detailed financials for Intas
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intas Comparisons
Peer comparison for Intas
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Intas
Detailed competitors of Intas
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intas
Complete news archive for Intas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intas
Intas was founded in 1977 and raised its 1st funding round 28 years after it was founded.
Intas is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
Rajendra Kumar is the current CEO of Intas.
Intas is a funded company, having raised a total of $199.57M across 4 funding rounds to date.
As of Feb 28, 2025, the latest employee count at Intas is 19,974.
Annual revenue of Intas is $2.41B as on Mar 31, 2023.
Intas was founded in 1977 in Ahmedabad, India, as a pharmaceutical company focused on formulation development, drug manufacturing, and marketing. Recombinant DNA protein products and plasma-derived therapies are developed for therapeutic areas including oncology, autoimmune diseases, ophthalmology, nephrology, and plasma-based treatments. A range of formulations, from tablets and capsules to injectables and advanced drugs, is offered to support various medical needs.
Intas offers Pharmaceutical Formulations and Biologics.
Intas has made 2 acquisitions, including Bioxel Pharma, and Udenyca.
Intas has 2 investors. Key investors include ChrysCapital, and Tata Capital Healthcare Fund.
The valuation of Intas is $866.44M as of Apr 2012.